ACT Brief: Who Sets Trial Endpoints, Human-Centered Trial Execution, and Bladder Cancer Approval Expansion

In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.